VTCN1 and cancer: Antibodies against PD-1, CTLA-4, and PD-L1—collectively known as ICIs—have demonstrated substantial efficacy in treating cancers, such as melanoma and lung cancer 12,13, while therapies targeting B7-H4 are entering clinical trials 14.